BioSpace News Archive

Drug Development

COVID-19 Brief: Vaccinations for 5 and Under Coming as Omicron Proves More Dangerous

Dr. Anthony Fauci expects the FDA will authorize the Pfizer-BioNTech vaccine for children under the age of five in the next month.

January 20, 2022
·
6 min read
·
Mark Terry
BioMidwest

Research Roundup: Nanotherapy and Islet Transplants for Diabetes and More

For about a century, the way to treat Type 1 diabetes has been via insulin injections. Although research has been conducted on pancreatic islet transplants, it’s a tough nut to crack in terms of organ rejection. There’s been a potential breakthrough in that area involving nanotherapy.

January 20, 2022
·
5 min read
·
Mark Terry
BioForest

Drug-Resistant Bacterium Second Only to COVID-19 for Leading Cause of Death by Infection

Infections caused by drug-resistant bacteria kill nearly as many people worldwide as HIV and malaria combined.

January 20, 2022
·
3 min read
·
Kate Goodwin
Business

BioSpace Movers & Shakers, Jan. 21

Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth.

January 20, 2022
·
8 min read
·
Alex Keown
Business

Merck’s Clyburn Departs for Different Healthcare Realm

Merck announced that Frank Clyburn, executive vice president and president of human health, will be leaving the company on February 1, 2022.

January 20, 2022
·
2 min read
·
Mark Terry
Business

Foresite Labs Hatches Big-Data-Driven Companies Destined to Shake up Healthcare

Such a deep, data-driven approach is enabling precision medicine, in particular, which is expanding from oncology to autoimmune diseases and other conditions.

January 20, 2022
·
5 min read
·
Gail Dutton
Deals

Unilever Throws in the Towel on GSK Business Buy after Rejection

Unilever announced Wednesday that it will not increase its bid over the recently proposed £50 billion (about $68 billion) to ensure that the acquisitions create value for its shareholders.

January 20, 2022
·
2 min read
·
Alex Keown
Drug Development

ImmPACT Bio Gains $111M, a New Leader and Positive Trial Results

ImmPACT Bio provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy.

January 20, 2022
·
3 min read
·
Hayley Shasteen
Business

Tennis Star Bets on a Grand Slam as 80% Shareholder in Danish Biotech

World tennis superstar Novak Djokovic reportedly has an 80% stake in QuantBioRes that’s currently working on finding a treatment, not a vaccine, for COVID-19.

January 20, 2022
·
2 min read
·
Vanessa Doctor, RN
Drug Development

The Pipeline Gets the Cash as Zymeworks Trims 25% of Staff

As part of a company-wide workforce reduction, it will cut its employee headcount by at least 25% by the end of the year, and 50% of its senior management team are leaving the company.

January 20, 2022
·
2 min read
·
Mark Terry